...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults
【24h】

Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults

机译：顺序开放标签研究，对健康泰国成年人的二氢氨苄蛋白 - 哌啶素 - 稻瘟病和Mefloquine之间的安全性，耐受性和药代动力学相互作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Artemisinin-based combination therapies (ACTs) have contributed substantially to the global decline in Plasmodium falciparum morbidity and mortality, but resistance to artemisinins and their partner drugs is increasing in Southeast Asia, threatening malaria control. New antimalarial compounds will not be generally available soon. Combining three existing antimalarials in the form of triple ACTs, including dihydroartemisinin (DHA)-piperaquine + mefloquine, is a potential treatment option for multidrug-resistant Plasmodium falciparum malaria. In a sequential open label study, healthy Thai volunteers were treated with DHA-piperaquine (120 to 960 mg), mefloquine (500 mg), and DHA-piperaquine + mefloquine (120 to 960 mg + 500 mg), and serial symptom questionnaires, biochemistry, full blood counts, pharmacokinetic profiles, and electrocardiographic measurements were performed. Fifteen healthy subjects were enrolled. There was no difference in the incidence or severity of adverse events between the three treatment arms. The slight prolongation in QTc (QT interval corrected for heart rate) associated with DHA-piperaquine administration did not increase after administration of DHA-piperaquine + mefloquine. The addition of mefloquine had no significant effect on the pharmacokinetic properties of piperaquine. However, coadministration of mefloquine significantly reduced the exposures to dihydroartemisinin for area under the concentration-time curve (-22.6%; 90% confidence interval [Cl],-33.1,-10.4; P = 0.0039) and maximum concentration of drug in serum (-29.0%; 90% CI,-40.6,-15.1; P = 0.0079). Mefloquine can be added safely to dihydroartemisinin-piperaquine in malaria treatment. (This study has been registered at ClinicalTrials.gov under identifier NCT02324738.)
机译：基于青蒿素的组合疗法（行为）基本上促进了恶性疟原虫发病率和死亡率的全球下降，但对罂粟蛋白和其伴侣药物的抗性在东南亚正在增加，威胁疟疾控制。新的抗疟性化合物通常不会很快发布。将三种现有的抗疟药组合在三重行为的形式中，包括二氢氨基氨苄蛋白（DHA）-Piperaquine + Mefloquine，是用于多药抗性疟原虫疟疾的潜在治疗选择。在一项顺序开放标签研究中，健康的泰国志愿者被DHA-稻瘟（120至960毫克），Mefloquine（500mg）和Dha-piperaquine + mefloquine（120至960 mg + 500 mg）治疗，以及串行症状问卷，进行生物化学，全血计数，药代动力学谱和心电图测量。已注册十五个健康的科目。三个治疗臂之间的不良事件发生率或严重程度没有差异。 QTC（QT间隔矫正心率）与DHA-稻瘟施用相关的QTC（QT间隔）的轻微延长在施用DHA-哌啶+ Mefloquine后没有增加。含有mefloquine对哌喹的药代动力学性质没有显着影响。然而，Mefloquine的共同分子显着降低了浓度 - 时间曲线下的面积的曝光对二氢氨基氨基（-22.6％; 90％置信区间[Cl]， - 33.1，-10.4; p = 0.0039）和血清中的最大浓度（ -29.0％; 90％CI，-40.6，-15.1; p = 0.0079）。可以安全地加入Meflooquine在疟疾治疗中安全地添加到二氢氨基异素蛋白蛋白。 （本研究已在临床节中注册在标识符NCT02324738下。）

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号